The Chromatin-binding Protein HMGN1 Regulates the Expression of Methyl CpG-binding Protein 2 (MECP2) and Affects the Behavior of Mice*

Background: HMGN1 is a chromatin-binding protein that modulates the cellular transcription profile. Results: Mice that either overexpress or lack HMGN1 have altered behavioral phenotypes. HMGN1 is a negative regulator of MeCP2, a protein involved in neurodevelopmental disorders. Conclusion: Misregulation of HMGN1 protein levels lead to behavioral changes in mice. Significance: HMGN1 is an epigenetic factor that contributes to the development of neurodevelopmental disorders. High mobility group N1 protein (HMGN1), a nucleosomal-binding protein that affects the structure and function of chromatin, is encoded by a gene located on chromosome 21 and is overexpressed in Down syndrome, one of the most prevalent genomic disorders. Misexpression of HMGN1 affects the cellular transcription profile; however, the biological function of this protein is still not fully understood. We report that HMGN1 modulates the expression of methyl CpG-binding protein 2 (MeCP2), a DNA-binding protein known to affect neurological functions including autism spectrum disorders, and whose alterations in HMGN1 levels affect the behavior of mice. Quantitative PCR and Western analyses of cell lines and brain tissues from mice that either overexpress or lack HMGN1 indicate that HMGN1 is a negative regulator of MeCP2 expression. Alterations in HMGN1 levels lead to changes in chromatin structure and histone modifications in the MeCP2 promoter. Behavior analyses by open field test, elevated plus maze, Reciprocal Social Interaction, and automated sociability test link changes in HMGN1 levels to abnormalities in activity and anxiety and to social deficits in mice. Targeted analysis of the Autism Genetic Resource Exchange genotype collection reveals a non-random distribution of genotypes within 500 kbp of HMGN1 in a region affecting its expression in families predisposed to autism spectrum disorders. Our results reveal that HMGN1 affects the behavior of mice and suggest that epigenetic changes resulting from altered HMGN1 levels could play a role in the etiology of neurodevelopmental disorders.

[1]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[2]  J. Silverman,et al.  Automated Three‐Chambered Social Approach Task for Mice , 2011, Current protocols in neuroscience.

[3]  Diana V. Dugas,et al.  Protein Interactome Reveals Converging Molecular Pathways Among Autism Disorders , 2011, Science Translational Medicine.

[4]  S. Horvath,et al.  Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology , 2011, Nature.

[5]  Michael Bustin,et al.  Effects of HMGN variants on the cellular transcription profile , 2011, Nucleic acids research.

[6]  Dustin E. Schones,et al.  Genomic Profiling of HMGN1 Reveals an Association with Chromatin at Regulatory Regions , 2010, Molecular and Cellular Biology.

[7]  Stylianos E. Antonarakis,et al.  Down Syndrome: From Understanding the Neurobiology to Therapy , 2010, The Journal of Neuroscience.

[8]  R. Ghosh,et al.  Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin , 2010, IUBMB life.

[9]  Tsun-Po Yang,et al.  Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..

[10]  B. Chung,et al.  Autism spectrum disorders and epigenetics. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[11]  Margaret A. Pericak-Vance,et al.  A genome-wide scan for common alleles affecting risk for autism , 2010, Human molecular genetics.

[12]  Gary D Bader,et al.  Functional impact of global rare copy number variation in autism spectrum disorders , 2010, Nature.

[13]  C. Lord,et al.  Behavioural phenotyping assays for mouse models of autism , 2010, Nature Reviews Neuroscience.

[14]  H. Bokhoven,et al.  Disruption of the epigenetic code: An emerging mechanism in mental retardation , 2010, Neurobiology of Disease.

[15]  C. Dulac.  Brain function and chromatin plasticity , 2010, Nature.

[16]  S. Peters,et al.  The MECP2 duplication syndrome , 2010, American journal of medical genetics. Part A.

[17]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[18]  R. Kooy.  Distinct disorders affecting the brain share common genetic origins , 2010, F1000 biology reports.

[19]  H. Hakonarson,et al.  Genetic Determinants of Pediatric Inflammatory Bowel Disease: Is Age of Onset Genetically Determined? , 2009, Digestive Diseases.

[20]  M. Gerstein,et al.  The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies , 2009, Proceedings of the National Academy of Sciences.

[21]  P. Giresi,et al.  Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). , 2009, Methods.

[22]  Robert T. Schultz,et al.  Common genetic variants on 5p14.1 associate with autism spectrum disorders , 2009, Nature.

[23]  Joseph T. Glessner,et al.  Genome wide association (GWA) predictors of anti‐TNF&agr; therapeutic responsiveness in pediatric inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[24]  A. Razin,et al.  MeCP2 involvement in the regulation of neuronal alpha-tubulin production. , 2009, Human molecular genetics.

[25]  S. Antonarakis,et al.  Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21 , 2009, European Journal of Human Genetics.

[26]  G. Gerlitz,et al.  The dynamics of HMG protein-chromatin interactions in living cells. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[27]  E. Shimada,et al.  Expression of the congenital heart disease 5/tryptophan rich basic protein homologue gene during heart development in Medaka fish, Oryzias latipes , 2009, Development, growth & differentiation.

[28]  D. Reiss,et al.  Triangular Relationships in Adolescence Predict Adult Psychopathology: an Empirical Validation of the Oedipus Complex? , 2008, Journal of the American Psychoanalytic Association.

[29]  M. Biran,et al.  Summaries of the Sixth Annual Poster Session of the American Psychoanalytic Association: Part I , 2008, Journal of the American Psychoanalytic Association.

[30]  Joseph T. Glessner,et al.  Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease , 2008, Nature Genetics.

[31]  A. Bird.  The methyl-CpG-binding protein MeCP2 and neurological disease. , 2008, Biochemical Society transactions.

[32]  Rodney C. Samaco,et al.  A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. , 2008, Human molecular genetics.

[33]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[34]  M. Bieda,et al.  Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.

[35]  A. Razin,et al.  MeCP2 Deficiency in the Brain Decreases BDNF Levels by REST/CoREST-Mediated Repression and Increases TRKB Production , 2007, Epigenetics.

[36]  Sudha Seshadri,et al.  Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes , 2007, BMC Medical Genetics.

[37]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[38]  V. Iyer,et al.  FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. , 2007, Genome research.

[39]  J. Crabbe,et al.  The parallel rod floor test: a measure of ataxia in mice , 2007, Nature Protocols.

[40]  J. LaSalle,et al.  Reduced MeCP2 Expression is Frequent in Autism Frontal Cortex and Correlates with Aberrant MECP2 Promoter Methylation , 2006, Epigenetics.

[41]  C. Epstein,et al.  The challenge of Down syndrome. , 2006, Trends in molecular medicine.

[42]  U. Francke,et al.  Identification of cis-regulatory elements for MECP2 expression. , 2006, Human molecular genetics.

[43]  M. Bustin,et al.  Distinct Domains in High Mobility Group N Variants Modulate Specific Chromatin Modifications* , 2006, Journal of Biological Chemistry.

[44]  R. Jaenisch,et al.  Postnatal Loss of Methyl-CpG Binding Protein 2 in the Forebrain is Sufficient to Mediate Behavioral Aspects of Rett Syndrome in Mice , 2006, Biological Psychiatry.

[45]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[46]  H. Zoghbi,et al.  Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. , 2005, Human molecular genetics.

[47]  H. Zoghbi,et al.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. , 2004, Human molecular genetics.

[48]  J. Piven,et al.  Automated apparatus for quantitation of social approach behaviors in mice , 2004, Genes, brain, and behavior.

[49]  M. Bustin,et al.  Chromosomal protein HMGN1 modulates histone H3 phosphorylation. , 2004, Molecular cell.

[50]  Michael Bustin,et al.  Chromosomal protein HMGN1 enhances the rate of DNA repair in chromatin , 2003, The EMBO journal.

[51]  M. Cuccaro,et al.  Identification of MeCP2 mutations in a series of females with autistic disorder. , 2003, Pediatric neurology.

[52]  T. Misteli,et al.  Competition between histone H1 and HMGN proteins for chromatin binding sites , 2002, EMBO reports.

[53]  R. Jaenisch,et al.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice , 2001, Nature Genetics.

[54]  A. Razin,et al.  CpG methylation, chromatin structure and gene silencing—a three‐way connection , 1998, The EMBO journal.

[55]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[56]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[57]  R. Reeves,et al.  Characterization of transgenic mice with an increased content of chromosomal protein HMG-14 in their chromatin. , 1995, DNA and cell biology.

[58]  M. Bustin,et al.  Homodimers of chromosomal proteins HMG-14 and HMG-17 in nucleosome cores. , 1995, Journal of molecular biology.

[59]  M. Bustin,et al.  The HMG-14/-17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates. , 1995, Seminars in cell biology.

[60]  H. Ding,et al.  Stimulation of RNA polymerase II elongation by chromosomal protein HMG-14. , 1994, Science.

[61]  M. Bustin,et al.  Immunochemical analysis of the exposure of high mobility group protein 14 and 17 surfaces in chromatin. , 1990, The Journal of biological chemistry.

[62]  S. Rapoport,et al.  Chromosomal protein HMG-14 gene maps to the Down syndrome region of human chromosome 21 and is overexpressed in mouse trisomy 16. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[63]  M. Bustin,et al.  Persistence of chromosomal proteins HMG-14/-17 in myotubes following differentiation-dependent reduction of HMG mRNA. , 1990, The Journal of biological chemistry.

[64]  M. Bustin,et al.  Immunological relatedness of high mobility group chromosomal proteins from calf thymus. , 1978, The Journal of biological chemistry.

[65]  R. Hock,et al.  Binding and interplay of HMG proteins on chromatin: lessons from live cell imaging. , 2010, Biochimica et biophysica acta.

[66]  M. Bustin,et al.  Regulation of chromatin structure and function by HMGN proteins. , 2010, Biochimica et biophysica acta.

[67]  Y. Pawitan,et al.  Regions of homozygosity and their impact on complex diseases and traits , 2010, Human Genetics.

[68]  A. Bird,et al.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome , 2001, Nature Genetics.

[69]  M. Coussons‐Read,et al.  Behavioral assessment of the Ts65Dn mouse, a model for down syndrome: Altered behavior in the elevated plus maze and open field , 1996, Behavior genetics.

[70]  J. Delabar,et al.  Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.